{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-25-000054","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.092047+00:00","generated_at":"2026-05-17T23:10:22.612711+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LENZ reports Q2 net loss $14.9M; LNZ100 PDUFA on track for Aug 8, 2025","bullets":["Cash, cash equivalents and marketable securities $209.6M as of June 30, 2025; >$205M expected by PDUFA date.","Net loss $14.9M ($0.53 per share) for Q2 2025 vs $10.3M ($0.40) in Q2 2024.","NDA for LNZ100 (aceclidine for presbyopia) under FDA review; PDUFA target Aug 8, 2025; no advisory committee.","Commercial team of 88 sales force hired and trained; launch ready upon FDA approval.","Executed multiple international license deals totaling >$195M potential milestones plus double-digit royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-25-000054","json":"https://secwatch.observer/filing/0001815776-25-000054.json","markdown":"https://secwatch.observer/filing/0001815776-25-000054.md","text":"https://secwatch.observer/filing/0001815776-25-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/0001815776-25-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/lenz-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:10:22.612711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}